Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel disease

BACKGROUND: Atypical hemolytic uremic syndrome is a rare group of disorders that have in common underlying complement amplifying conditions. These conditions can accelerate complement activation that results in a positive feedback cycle. The known triggers for complement activation can be diverse an...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Thromb J
Autors principals: Hanna, Ramy M., Merin, Noah, Burwick, Richard M., Abdelnour, Lama, Selamet, Umut, Yanny, Beshoy, Bui, Patrick, Fouad, Mary, Kurtz, Ira
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2019
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6732828/
https://ncbi.nlm.nih.gov/pubmed/31516395
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12959-019-0207-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars